Views: 0 Author: Site Editor Publish Time: 2026-03-20 Origin: Site
According to Future Market Insights, the global tablet press machines market is estimated at USD 1.6 billion in 2025. It’s projected to reach USD 2.6 billion by 2035, growing at a 5.3% CAGR. Source
The core drivers aren’t complicated. Rising pharma demand, tighter compliance requirements, and a clear push toward automation are doing most of the work. Source
What’s changing in 2026 is the type of demand. Buyers no longer just ask for raw capacity.
They want flexible production and multi-layer tablet capability.
Cadmach sits at an interesting intersection. It’s Indian-made, globally shipped, and priced for markets where ROI cycles are short.
That’s a defensible position.
Cadmach structures its range clearly. Entry-level is the CMD series. High-volume production is the Cadpress series.
Each tier has a different buyer.
CMD3 is a non-GMP single rotary press. It’s positioned for low-investment starts.
The numbers are honest for what it is.
Output: 14,400 to 28,800 tablets/hour
Max operating pressure: 10 tons
Max tablet diameter: 25 mm
Stations: 16, D tooling (CMD3-16) or special tooling with 30 mm fill depth (CMD3-16/30)
The 30 mm fill depth option is useful. It handles OTC tablets and large supplement formats.
That’s a practical advantage for herbal and Ayurvedic producers.
CMD4 is the step up. It’s cGMP-compliant and built for pilot batch production.
PLC touchscreen control and auto lubrication are standard features here.
CMD4-20: 20 stations, D tooling, 22,800 to 50,400 tablets/hour, 10 tons max pressure
CMD4-25: 25 stations, B tooling, 28,500 to 63,000 tablets/hour
CMD4-12DX: 12 stations, special tooling for bolus applications, up to 36 mm tablet diameter
The bolus variant is notably wide. A 36 mm max tablet diameter covers veterinary and specialty dosage forms.
That’s a niche most buyers overlook.
This is Cadmach’s serious production platform. Over 20 years in service with a proven track record.
The output range is wide, and it scales with station count.
| Configuration | Stations | Tooling | Max Output (tablets/hour) | Main Compaction Force |
|---|---|---|---|---|
| CPD IV-45 | 45 | D | 65,000–324,000 | 100 kN |
| CPD IV-55 | 55 | B | 79,000–396,000 | 65 kN |
| CPD IV-69 | 69 | BB | 99,000–497,000 | 65 kN |
| CPD IV-75 | 75 | BB | 108,000–540,000 | 65 kN |
The Cadpress IV also includes SCADA with 15-inch touchscreen, Compaction Force Control (CFC) for auto weight management, and single tablet rejection at max speed.
That’s not entry-level software. It’s real production monitoring.
This is where Cadmach genuinely stands apart. Tab-in-Tab (tablet-in-tablet) pressing is rare.
Cadmach states it’s one of the few suppliers in the world to achieve this efficiently.
The CPC 20 has been in the market for over 15 years. Nominal output is 24,000 tablets/hour.
For complex dosage forms requiring physical API separation, this isn’t just a nice feature. It’s the solution.
CapEx is only part of the story. TCO is the real metric.
Here’s how Cadmach stacks up in 2026.
| Brand / Model | Core Strength | Geographic Coverage | 2026 Position | Price Range (USD) |
|---|---|---|---|---|
| Cadmach (CMD / Cadpress IV) | Tab-in-Tab, high-value price point | India (strong), global export | Asia-Pacific volume leader | $50k–$200k |
| Korsch (XT / XM) | Extreme precision, continuous tableting | Europe and North America | Premium segments | $300k–$800k |
| Hanyoo (HY-Series) | AI quality monitoring, modular OEM | Global, China-based manufacturing | Fastest-growing segment | $45k–$180k |
The logic is simple. A clean ROI model keeps the conversation honest:
ROI = ( (P_hourly × H_year × (1 − R_waste)) − C_maintenance ) / P_initial × 100%
For a CPD IV-75 running at 400,000 tablets/hour sustained, the math can be compelling.
Cadmach’s India-based spare parts supply keeps C_maintenance lower than European alternatives.
Cadmach’s engineering is solid. But two areas often prompt buyers to compare further.
AI-driven quality monitoring: Cadmach’s SCADA approach handles force data and weight correction. Hanyoo’s pitch in 2026 focuses on real-time humidity-driven micro-adjustments. The claimed waste rate difference is roughly 5% vs. 2.5%. That’s meaningful at high volumes.
Global compliance documentation: For exports into Europe or North America, full CE and FDA 21 CFR Part 11 documentation packages matter. Buyers sometimes find this process easier with China-based suppliers who’ve already mapped that paperwork path.
OEM speed: Hanyoo claims roughly 2-week modular tooling turnaround. For high-mix, low-volume operations, that kind of responsiveness changes production planning.
Simple rule of thumb: if your primary market is India or South Asia and you want proven hardware with local support, Cadmach earns its reputation. If you’re optimizing for global markets with AI quality control and rapid OEM cycles, Hanyoo offers a different ROI story.
Validate real-world throughput: request a continuous 24-hour run log at operating RPM. Rated max output and sustained output often diverge.
Pressure consistency at FAT: watch the standard deviation of compaction force readings. That’s where quality gaps appear fastest.
Spare parts logistics: confirm a 48-hour response parts center near your facility. Downtime is always the budget line nobody writes down.
Compliance audit now: if FDA 21 CFR Part 11 compliance is needed, clarify it before signing. Retrofitting electronic records capability after installation is expensive.
Q: How stable is Cadmach’s multi-layer tablet press?
A: The Tab-in-Tab CPC 20 supports tablet-in-tablet production. Nominal output is around 24,000 tablets/hour. Source
Physical API separation is the value here, not raw speed. For incompatibility challenges, it’s one of the better-tested solutions available.
Q: What’s the tariff risk on Cadmach equipment in 2026?
A: RCEP and bilateral trade agreements are gradually lowering tariffs on Indian pharma machinery.
Always verify the declared OEM country of origin. Anti-dumping provisions can still complicate the landed cost picture.
